Since small molecule inhibitors of TG2 are currently available (Kim, 2018) and anti-TG2 monoclonal antibodies are being developed, these novel therapeutics may prove to be useful in modifying tissue stiffness occurring with alterations in tissue pressure-overload, diabetes, obesity/metabolic syndrome or aging. This evidence concerns the gene TGM2 and diabetes mellitus.